Suggested remit: To appraise the clinical and cost effectiveness of zanidatamab within its marketing authorisation for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments.
 
Status In progress
Technology type Medicine
Decision Awaiting decision
Process STA Standard
ID number 6388

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6388 04 March 2025 - 01 April 2025

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
04 March 2025 In progress. Scoping commencing
24 November 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
24 November 2023 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual